Show simple item record

dc.contributor.authorWest, Catharine M L
dc.contributor.authorStratford, Ian J
dc.date.accessioned2010-11-08T10:33:16Z
dc.date.available2010-11-08T10:33:16Z
dc.date.issued1987
dc.identifier.citationA comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids. 1987, 20 (2):109-14 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704
dc.identifier.pmid2822273
dc.identifier.doi10.1007/BF00253963
dc.identifier.urihttp://hdl.handle.net/10541/114924
dc.description.abstractMulticellular spheroids were used to compare the two chemotherapeutic agents adriamycin (ADM) and 4'[(9-acridinyl)-amino] methanesulphon-m-anisidide (mAMSA). Chinese hamster cells, V79 379A, a human small cell lung carcinoma, designated ME/MAR, and a human melanoma xenograft, HX117, were grown as spheroids (200 or 400 micron in diameter) and treated with either drug for 1 h, at 37 degrees C, in air. Cytotoxicity was assayed using both cell survival and growth delay. Both drugs were highly toxic towards V79 but showed less activity toward the human tumour single cell suspensions; ADM was more effective towards HX117 and ME/MAR than mAMSA. When grown as spheroids, the cells developed marked resistance to both drugs. In all cases, cytotoxicity was drug dose and spheroid size dependent. The response of HX117 spheroids to both drugs was similar. In contrast, ADM was more effective toward 200 micron diameter ME/MAR spheroids, and mAMSA showed greater activity than ADM against V79 spheroids. Both endpoints gave qualitatively equivalent results, and a comparison of the two showed relatively long growth delays for a given level of cell kill, for both drugs and with all three cell lines. The greater cytotoxicity of ADM toward ME/MAR spheroids is consistent with the clinical finding that ADM has a use in the treatment of small cell carcinoma of the lung, while mAMSA has not demonstrated any activity in the treatment of lung cancer.
dc.language.isoenen
dc.subjectCultured Tumour Cellsen
dc.subjectLung Canceren
dc.subject.meshAmsacrine
dc.subject.meshAnimals
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshCell Survival
dc.subject.meshCricetinae
dc.subject.meshCricetulus
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDoxorubicin
dc.subject.meshDrug Screening Assays, Antitumor
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMelanoma
dc.subject.meshTumor Cells, Cultured
dc.titleA comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstractMulticellular spheroids were used to compare the two chemotherapeutic agents adriamycin (ADM) and 4'[(9-acridinyl)-amino] methanesulphon-m-anisidide (mAMSA). Chinese hamster cells, V79 379A, a human small cell lung carcinoma, designated ME/MAR, and a human melanoma xenograft, HX117, were grown as spheroids (200 or 400 micron in diameter) and treated with either drug for 1 h, at 37 degrees C, in air. Cytotoxicity was assayed using both cell survival and growth delay. Both drugs were highly toxic towards V79 but showed less activity toward the human tumour single cell suspensions; ADM was more effective towards HX117 and ME/MAR than mAMSA. When grown as spheroids, the cells developed marked resistance to both drugs. In all cases, cytotoxicity was drug dose and spheroid size dependent. The response of HX117 spheroids to both drugs was similar. In contrast, ADM was more effective toward 200 micron diameter ME/MAR spheroids, and mAMSA showed greater activity than ADM against V79 spheroids. Both endpoints gave qualitatively equivalent results, and a comparison of the two showed relatively long growth delays for a given level of cell kill, for both drugs and with all three cell lines. The greater cytotoxicity of ADM toward ME/MAR spheroids is consistent with the clinical finding that ADM has a use in the treatment of small cell carcinoma of the lung, while mAMSA has not demonstrated any activity in the treatment of lung cancer.


This item appears in the following Collection(s)

Show simple item record